The pioneering work of Vaiomer founders
It all started with the pioneering work of Vaiomer’s founders. They were working on the link between gut microbiota and diabetes, obesity and cardiovascular diseases.
The gut microbiome had been proven to be causal to diabetes, obesity, inflammation and metabolic diseases, among other environmental factors and genetic predispositions.
They suggested that during high-fat diet-induced diabetes, commensal intestinal bacteria translocate in a pathological manner from the intestine towards the tissue, where they trigger a local inflammation. They showed that at the early onset of HFD-induced diabetes and obesity in mice, there is an increase of the translocation of commensal bacteria into the adipose tissue. These bacteria and/or bacterial products then co-localize with dendritic cells of the intestinal lamina propria and the mesenteric lymph nodes when diabetes is established (Amar et al., 2011, EMBO).
They also showed for the first time in blood that 16S rDNA was an independent marker of the risk of diabetes and abnormal adiposity in a general population (Amar et al., 2011, Diabetologia).
These findings established evidence for the concept of the involvement of blood and tissue bacteria in the onset of diabetes in humans.
While NGS technologies were emerging, there was a critical need for methods suitable to explore low bacterial content tissues. In 2011, Vaiomer was funded to develop this cutting-edge technology to investigate the role of circulating microbiomes in homeostasis and diseases.
Vaiomer’s early achievements granted by the scientific community
The first publication in 2015 established Vaiomer newly developed targeted metagenomics pipeline for the investigation of the microbiome in a variety of mouse tissues including brain, muscle, adipose tissue, liver and heart (Lluch et al., 2015, PLoS One).
Following the successful development of methods dedicated to low bacterial biomass samples Vaiomer presented the first comprehensive description of the blood microbiome of healthy donors (Païssé et al., 2016, Transfusion). This was the basis for the discovery of a potential biomarker of Liver Fibrosis in the blood of obese patients (Lelouvier et al., 2016, Hepatology). It also revealed an unexpected case of infection of a patient hospitalized for myocardial infarction complicated by heart failure (Lelouvier et al., 2017, J Infect), when comparing the blood microbiomes of patients with acute coronary syndrome to the one of subjects at high cardiovascular risk but without coronary syndrome. This comparison revealed a blood signature of Myocardial Infarction useful as a biomarker for the stratification of MI patients (Amar et al., 2019, J Am Heart Assoc).
Vaiomer molecular biology lab
Each area of the lab is dedicated to a specific step of the processing of your precious samples, from reception to extraction and analysis.
A very particular attention is brought to the extraction step, performed in our L2 under safety hood, in order to protect our personnel and your samples from contamination. Each kind of tissue/fluid undergoes a specific extraction procedure.
We handle your samples through all analysis steps with state of the art equipment, including an EVO150 robot from TECAN and Illumina MiSeq sequencers. All consumables and reagents are carefully selected. QC is performed at each step in order to ensure the success of your project and control for potential contaminants.
Our laboratory team is particularly educated and attentive to contamination management, in order to protect your valuable biological samples. Our competent staff is trained to handle samples of infectious individuals, according to French Safety Regulations (Regional Health Agencies /French Ministry of Solidarity and Health).
Your first line expert team
Vaiomer expert team is dedicated to the success of your projects. The complementary profiles of the senior scientists contribute to the global expertise of the company in the field of molecular biology, high-throughput sequencing, bioinformatics, microbial ecology, microbiome analysis and its applications in basic and applied research in humans and animals.
Chief Executive Officer
Jérôme leads the strategic development and oversees the management at Vaiomer.
- MSc in Finance from ESC Toulouse
- Jérôme has 20 years of experience investing and participating in the strategic development of listed companies and start-ups such as Energisme (software for energy saving), Wiseed (crowd-funding) and Sensee (web sales platform)
- With his last fund management company, Jérôme has invested in numerous listed biotech companies (e.g. Nanobiotix, Valbiotis, Transgene, Genfit and Medincell). Thanks to this experience, he has gained a better understanding of the business model, the opportunities and the risks in the development of biotech companies
- Jérôme joined Vaiomer in 2021 as CEO
Sales & Marketing Director
Anne is your first line contact at Vaiomer and is dedicated to the success of your microbiome study.
- MSc in molecular biology and bioengineering
- 20+ years of experience in international business development of products and services in life sciences towards biotech, pharmaceutical and food ingredient industries as well as academia (from biomanufacturing to sequencing to human monoclonal antibody generation technology)
- Anne joined Vaiomer in 2015, where she developed the microbiome analysis service offer
- She coordinates customer requests and studies from the early stages of the project conception to the support of their valorisation
Chief Scientific Officer
Benjamin is your partner to valorise your microbiome studies and a regular co-author of customer publications.
- Ph.D in Neurobiology from the University Pierre et Marie Curie-Paris VI, France
- 5-year postdoc at the National Institutes of Health (USA)
- Benjamin joined Vaiomer in 2012, where he has been instrumental in the development of the molecular methods to explore the blood and tissue microbiomes
- He published several works on the role of tissue and blood microbiomes in health and diseases, applied to clinical biomarker discovery
- Benjamin is the project leader for Vaiomer and co-founder of the European Project H2020 Microb Predict, for the prevention and treatment of chronic liver disease
- He advises customers from the experimental design to the elaboration of the final report of their study
Céline advises customers from the experimental design to the elaboration of the final report of their study.
- Ph.D in microbial ecology from Clermont Auvergne University, France, where she focused on the effects of environmental pollutants on gut microbiota and implemented a new molecular hybridization technique coupled to NGS technologies for the exploration of microbial communities
- 3.5-year postdoc at the APC Microbiome Ireland working for the development of a new probiotic candidate and as a bioinformatician in data and statistical analysis of microbiomes from human, animals, insects and in-vitro experiments
- Celine joined Vaiomer in 2020 as Microbiome Scientist
- She is your partner to valorize your study results
Head of bioinformatic department
Florence is expert in the development of high quality tools for data analysis and visualization, as well as quality control and automatic processing of large scale biological data.
- MSc in biology and computer science from Rennes I University, France
- 9-year fellowships in academia as bioinformatician in sequence analysis at INRAE in France, the European Bioinformatics Institute (EMBL-EBI) in the UK and McGill University in Canada
- 7 years at the Syngenta company in a global role to develop markers for assisted breeding from NGS data and to setup a functional genomics platform
- Florence joined Vaiomer in 2013 as head of the bioinformatics department where she has been instrumental in establishing the Vaiomer microbiome data analysis pipeline.
- Florence cumulates more than 20 years of experience in working with scientists from multidisciplinary environments, she enjoys listening to the questions from the customers and make the microbiome analysis results accessible to all audiences.
Alain manages the lab work and staff and is a driving force for Vaiomer technology development projects.
- Ph.D in molecular pharmacology from the Université Paul Sabatier-Toulouse, France
- 3-year postdoc at McGill University (Canada) at the parasitology institute where he set up the qPCR quantitation technical platform, followed by a 1-year postdoc at the Claudius Regaud Cancer Centre (France) on metastatic melanoma
- 4 years at the Toulouse genomic platform (Get-PlaGe) where he was responsible for long fragment sequencing projects on PacBio RSII and ONT platforms, new application developments with Illumina sequencing technologies and matrix qPCR projects with the microfluidic technology
- Strong capabilities in data analytics and statistics to support decision making process
- Alain joined Vaiomer in 2018 as Lab Manager
Travel through the fascinating history of microbiome!
Although gut microbiota is by far the most investigated, the concepts of gut and blood microbiomes have grown in parallel since the early stages of the field.
Are blood and tissue microbiota relevant to your project?
Join Anne for a first chat.
Sales & Marketing Director